WO2025017368 - METHODS FOR TREATING CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
National phase entry:
Publication Number
WO/2025/017368
Publication Date
23.01.2025
International Application No.
PCT/IB2024/000374
International Filing Date
16.07.2024
Title **
[English]
METHODS FOR TREATING CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
[French]
MÉTHODES DE TRAITEMENT D'UNE POLYNEUROPATHIE DÉMYÉLINISANTE INFLAMMATOIRE CHRONIQUE
Applicants **
ARGENX BV
Industriepark Zwijnaarde 7
9052 Ghent, BE
Inventors
HOFMAN, Erik
c/o Argenx BV
Industriepark Zwijnaarde 7
9052 Ghent, BE
PARYS, Wim
Edward Caertsstraat 39
2180 Ekeren, BE
BEELKE, Manolo
c/o Manolo Beelke & Partners
Schlucht 1
58849 Herscheid, DE
DINCQ, Stephanie
c/o Argenx BV
Industriepark Zwijnaarde 7
9052 Ghent, BE
LOWE, Murray
14 Overton Drive
West Kilbride KA23 9LH, GB
SEGHERS, Katarina
c/o Argenx BV
Industriepark Zwijnaarde 7
9052 Ghent, BE
DE PAEPE, Els
c/o Argenx BV
Industriepark Zwijnaarde 7
9052 Ghent, BE
VAN HOORICK, Benjamin
c/o Argenx BV
Industriepark Zwijnaarde 7
9052 Ghent, BE
ISTAS, Geoffrey
c/o Argenx BV
Industriepark Zwijnaarde 7
9052 Ghent, BE
JIANG, Ming
c/o Argenx BV
Industriepark Zwijnaarde 7
9052 Ghent, BE
GUPTILL, Jeffrey
c/o Argenx BV
Industriepark Zwijnaarde 7
9052 Ghent, BE
BEAUCHAMP, Jon
c/o Argenx BV
Industriepark Zwijnaarde 7
9052 Ghent, BE
TRUYEN, Luc
c/o Argenx BV
Industriepark Zwijnaarde 7
9052 Ghent, BE
Priority Data
2310890.5
16.07.2023
GB
63/617,702
04.01.2024
US
63/662,098
20.06.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 7454 | |
| EPO | Filing, Examination | 156677 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 640 | |
| USA | Filing, Examination | 45860 |
Total: 211222 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to methods of treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) using an antagonist of human neonatal Fc receptor (FcRn), which in certain embodiments is efgartigimod.[French]
La présente invention concerne des méthodes de traitement de la polyneuropathie démyélinisante inflammatoire chronique (PDIC) à l'aide d'un antagoniste du récepteur Fc néonatal (FcRn) humain, qui dans certains modes de réalisation est l'efgartigimod.